Mutations in the MAPK pathway, especially mutations in BRAF and MAP2K1, which account for nearly 80% of mutations in patients, are considered driver mutations in Langerhans cell histiocytosis (Figure 3B(a)). The gene discussed is MAP2K1; the disease is Langerhans cell histiocytosis.